OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study
In a multicentre phase 1 study, the recombinant overlapping peptide vaccine OVM-200 was found to be safe and well-tolerated while successfully breaking immune tolerance to the self-antigen survivin by inducing robust humoral and cellular immune responses in patients with advanced solid tumours, with higher immune responses correlating with stable disease.